• Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group 

      Katodritou E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., Kyrtsonis M.-C., Symeonidis A., Giannakoulas N., Vadikolia C., Michael M., Kalpadakis C., Gougopoulou T., Prokopiou C., Kaiafa G., Christoulas D., Gavriatopoulou M., Giannopoulou E., Labropoulou V., Verrou E., Kastritis E., Konstantinidou P., Anagnostopoulos A., Dimopoulos M.A. (2018)
      We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based ...
    • The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: Early results of a randomized trial 

      Alexidis P., Dragoumis D., Karatzoglou S., Drevelegas K., Tzitzikas I., Hatzimouratidis K., Chrisogonidis I., Giannakidis D., Koulouris C., Katsaounis A., Michalopoulos N., Huang H., Li Q., Aidoini Z., Fyntanidou V., Amaniti A., Hohenforst-Schmidt W., Maragouli E., Petanidis S., Zarogoulidis P., Sapalidis K., Kosmidis C., Romanidis K., Oinkonomou P., Vagionas A., Nikolaos-Katsios I., Ioannidis A., Boniou K., Kesisoglou I. (2019)
      Background: Prostate cancer is considered to have a special biology which could affect the radiation therapy result based on the selected fractionation scheme. We present the preliminary results of a randomized trial ...